Search citation statements

Order By: Relevance
Select...
1
1
1
1
0
8
0

Year Published

2015
2015
2018
2018

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

0
8
0
Order By: Relevance
“…In malignant tumors, HGF is primarily expressed and released by surrounding stromal cells, including CAFs and TAMs [ 16 , 55 ]. However, HGF can also be produced by several tumor cell types and is detected in the renal cell [ 56 ], colorectal [ 57 , 58 ] and breast carcinomas [ 59 , 60 ], glioma [ 61 ], multiple myeloma [ 62 ] and synovial [ 63 ], osteo- and fibrosarcoma [ 38 ]. On the other hand, the c-MET receptor is overexpressed in several solid tumors, such as medulloblastoma [ 64 ], lymphoma [ 65 ], melanoma [ 66 ], glioma [ 67 ], breast [ 68 ], pancreatic [ 69 ], colorectal, ovarian and prostate carcinomas, as well as osteo- and some soft-tissue sarcomas [ 38 ].…”
Section: Hgf/c-met Signaling Pathway Mediates Cancer Progressionmentioning
Create an account to read the remaining citation statements from this report. You will also get access to:
  • Search over 1.2b+ citation statments to see what is being said about any topic in the research literature
  • Advanced Search to find publications that support or contrast your research
  • Citation reports and visualizations to easily see what publications are saying about each other
  • Browser extension to see Smart Citations wherever you read research
  • Dashboards to evaluate and keep track of groups of publications
  • Alerts to stay on top of citations as they happen
  • Automated reference checks to make sure you are citing reliable research in your manuscripts
  • 7 day free preview of our premium features.

Trusted by researchers and organizations around the world

Over 130,000 students researchers, and industry experts at use scite

See what students are saying

rupbmjkragerfmgwileyiopcupepmcmbcthiemesagefrontiersapsiucrarxivemeralduhksmucshluniversity-of-gavle
“…In malignant tumors, HGF is primarily expressed and released by surrounding stromal cells, including CAFs and TAMs [ 16 , 55 ]. However, HGF can also be produced by several tumor cell types and is detected in the renal cell [ 56 ], colorectal [ 57 , 58 ] and breast carcinomas [ 59 , 60 ], glioma [ 61 ], multiple myeloma [ 62 ] and synovial [ 63 ], osteo- and fibrosarcoma [ 38 ]. On the other hand, the c-MET receptor is overexpressed in several solid tumors, such as medulloblastoma [ 64 ], lymphoma [ 65 ], melanoma [ 66 ], glioma [ 67 ], breast [ 68 ], pancreatic [ 69 ], colorectal, ovarian and prostate carcinomas, as well as osteo- and some soft-tissue sarcomas [ 38 ].…”
Section: Hgf/c-met Signaling Pathway Mediates Cancer Progressionmentioning
“…MSCs migrate towards breast cancer cells via hypoxia-induced interleukin 6 (IL6) secretion [ 47 ] and towards primary breast tumors via the hypoxia-inducible factor alpha (HIFα)-dependent secretion of CXCL16 [ 48 ]. Hypoxia-induced hepatocyte growth factor (HGF) may also mediate recruitment [ 49 ] as it is upregulated in serum of breast cancer patients [ 50 , 51 ] and associated with tumor formation and metastasis in breast [ 52 , 53 ] and prostate cancer [ 54 ]. Furthermore, the activation of HGF receptor, MET, in bone marrow stromal cells by melanoma cells is associated with metastasis [ 55 ].…”
Section: Mesenchymal Stromal Cells Within the Tumor Microenvironmementioning
“…Currently, many targeted approaches to cancer therapy have focused on the reliance of cancer cells on HGF/MET signaling for cell proliferation. Although approaches targeting MET, for instance diverse specific MET inhibitors, monoclonal antibodies and siMET, were developed, and have yielded promising results in preclinical studies, few clinical trials of MET inhibitors have demonstrated the expected therapeutic benefits [7]. This inconsistency raises the possibilities that there are different regulatory mechanisms of HGF/MET signaling in different cancers.…”
mentioning